Ex-Vivo Expanded Autologous Il-8 Receptor Modified Cd70 Car T Cells
Diffuse Intrinsic Pontine Glioma
Explore 28 assets in Diffuse Intrinsic Pontine Glioma →Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
University of Florida
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06946680CT.gov IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG) | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Intrinsic Pontine Glioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ex-Vivo Expanded Autologous Il-8 Receptor Modified Cd70 Car T Cells (this asset) | University of Florida | P1 | CC · 41 |
| Irinotecan | Actuate Therapeutics Inc. | P2 | BB |
| (+)-Vincristine | Julie Krystal | P2 | B |
| Nogitecan | Actuate Therapeutics Inc. | P2 | B |
| Indoximod | Theodore S. Johnson | P2 | B |
| Etoposide | Theodore S. Johnson | P2 | B |
| Ribociclib | Nationwide Children's Hospital | P2 | B |
| Cyclophosphamide | Shenzhen Geno-Immune Medical Institute | P2 | B |
| Everolimus | Nationwide Children's Hospital | P2 | B |
+33 more in the Diffuse Intrinsic Pontine Glioma cohort
Other indications for Ex-Vivo Expanded Autologous Il-8 Receptor Modified Cd70 Car T Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Glioma | — | P1 | CC · 43 |
| Glioblastoma | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ex-Vivo Expanded Autologous Il-8 Receptor Modified Cd70 Car T Cells in Diffuse Intrinsic Pontine Glioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ex-vivo-expanded-autologous-il-8-receptor-modified-cd70-car-t-cells-diffuse-intrinsic-pontine-glioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →